Shandong Kexing Bioproducts Co., Ltd. engages in the research and development, production, and sale of recombinant protein therapeutics and microbiota agents. Its products include recombinant human erythropoietin injections, recombinant human interferon a1b injections, recombinant human granulocyte stimulating factor injections, and clostridium butyricum double live bacteria powder and capsules. The company was founded on August 22, 1997 and is headquartered in Jinan, China.